Thermo Fisher Scientific’s ETD Mass Spec Technology Wins Silver Award at PITTCON 2007
News Mar 09, 2007
Thermo Fisher Scientific Inc. has received the Silver Editors’ Award at PITTCON 2007, the largest North American conference and exposition on laboratory science and instrumentation.
PITTCON editors voted the Thermo Scientific LTQ XL linear ion trap mass spectrometer featuring Electron Transfer Dissociation (ETD) technology which featured more than 1000 exhibitors.
ETD is designed to provide important peptide structural information not available from conventional collisionally induced dissociation (CID) methods. ETD is a fragmentation technique that can improve protein characterization, post-translational modification (PTM) analysis and top-down or middle-down sequencing of proteins and peptides.
The Thermo Scientific LTQ XL offers multiple dissociation techniques, Pulsed Q Dissociation (PQD), ETD and CID.
“We believe ETD performed on a linear ion trap is a major turning point for the proteomics community, enabling researchers to pinpoint, identify and fully characterize more post-transitional modificatons such as phosphorylation and glycosylation than ever before,” said Greg Herrema, president of Scientific Instruments at Thermo Fisher Scientific.
Recognition for ETD at PITTCON 2007 follows last year’s PITTCON Gold Editors’ Award for the Thermo Scientific LTQ Orbitrap hybrid mass spectrometer.
According to Company, ETD data is easily processed using a version of BioWorks software – both CID and ETD spectra are searched independently, with results from both searches combined for sorting and comparison. This system can provide the complete view of a proteome currently available.
Thermo Fisher Scientific showcased a wide range of products and laboratory solutions at PITTCON 2007, offering customers integrated technology and services, from sample preparation and analysis to data interpretation and storage.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.